Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2013, Pages 196-202

  Oh, Eun Sil ^a   Kim, Choon Ok ^a   Cho, Sung Kweon ^b   Park, Min Soo ^a,b   Chung, Jae Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

BCRP; MRP2; OATP1B1; Pharmacokinetic; Pitavastatin

Indexed keywords

PITAVASTATIN;

ABCC2 GENE; ABCG2 GENE; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; PROTEIN FUNCTION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; VOLUNTEER;

EID: 84879388830     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-068     Document Type: Article

References (45)

1. Wensel, T. M., Waldrop, B. A. and Wensel, B.: Pitavastatin: a new HMGCoA reductase inhibitor. Ann. Pharmacother., 44: 507-514 (2010).
2. Package insert. Livalo (pitavastatin). Montgomery, AL, Kowa Pharmaceuticals America, Inc., 2011.
3. Mukhtar, R., Reid, J. and Reckless, J.: Pitavastatin. Int. J. Clin. Pract., 59: 239-252 (2005).
4. Kajinami, K., Mabuchi, H. and Saito, Y.: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs, 9: 2653-2661 (2000).
5. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. and Sugiyama, Y.: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 68: 800-807 (2005).
6. Ieiri, I., Higuchi, S. and Sugiyama, Y.: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol., 5: 703-729 (2009).
7. Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H. and Irie, S.: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 82: 541-547 (2007).
8. Shirasaka, Y., Suzuki, K., Nakanishi, T. and Tamai, I.: Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J. Pharm. Sci., 100: 3843-3853 (2011).
9. Shirasaka, Y., Suzuki, K., Shichiri, M., Nakanishi, T. and Tamai, I.: Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/ multidrug resistance 1. Drug Metab. Pharmacokinet., 26: 171-179 (2011).
10. Hagenbuch, B. and Meier, P. J.: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta, 1609: 1-18 (2003).
11. Kivistö, K. T. and Niemi, M.: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res., 24: 239-247 (2007).
12. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y.: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther., 311: 139-146 (2004).
13. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Oh, D. S., Jung, H. R., Lim, K. S., Moon, K. H., Shin, S. G. and Jang, I. J.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 78: 342-350 (2005).
14. Wen, J. and Xiong, Y.: OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther., 35: 99-104 (2010).
15. Frolkis, J. P., Pearce, G. L., Nambi, V., Minor, S. and Sprecher, D. L.: Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am. J. Med., 113: 625-629 (2002).
16. Chan, L., Lowes, S. and Hirst, B. H.: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci., 21: 25-51 (2004).
17. Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Michael Stein, C. and Kim, R. B.: Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet. Genomics, 17: 647-656 (2007).
18. Niemi, M., Arnold, K. A., Backman, J. T., Pasanen, M. K., Gdtel-Armbrust, U., Wojnowski, L., Zanger, U. M., Neuvonen, P. J., Eichelbaum, M., Kivist, K. T. and Lang, T.: Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics, 16: 801-808 (2006).
19. Zhang, Y., Zhao, T., Li, W. and Vore, M.: The 5A-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol. Pharmacol., 77: 237-246 (2010).
20. Choi, J. H., Ahn, B. M., Yi, J., Lee, J. H., Nam, S. W., Chon, C. Y., Han, K. H., Ahn, S. H. and Jang, I. J.: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics, 17: 403-415 (2007).
21. Rau, T., Erney, B., Göres, R., Eschenhagen, T., Beck, J. and Langer, T.: High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther., 80: 468-476 (2006).
22. Naesens, M., Kuypers, D. R., Verbeke, K. and Vanrenterghem, Y.: Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation, 82: 1074-1084 (2006).
23. Miura, M., Satoh, S., Inoue, K., Kagaya, H., Saito, M., Inoue, T., Suzuki, T. and Habuchi, T.: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol., 63: 1161-1169 (2007).
24. Han, J., Lim, H., Yoo, Y., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J., Lee, D. H. and Kim, H. T.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 110: 138-147 (2007).
25. Zhou, Q., Sparreboom, A., Tan, E., Cheung, Y., Lee, A., Poon, D., Lee, E. J. and Chowbay, B.: Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol., 59: 415-424 (2005).
26. 1) rats. Drug Metab. Dispos., 39: 441-447 (2011).
27. Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. and Chiba, K.: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1* 5, SLCO1B1* 15 and SLCO1B1* 15+ C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics, 15: 513-522 (2005).
28. DeGorter, M., Kim, R. B., Liao, M., Yang, J. and Xia, C.: Drug Transporters in Drug Efficacy and Toxicity. Annu. Rev. Pharmacol. Toxicol., 52: 249-273 (2012).
29. Deng, J. W., Song, I. S., Shin, H. J., Yeo, C. W., Cho, D. Y., Shon, J. H. and Shin, J. G.: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics, 18: 424-433 (2008).
30. Ufer, M., Mosyagin, I., Muhle, H., Jacobsen, T., Haenisch, S., Hsler, R., Faltraco, F., Remmler, C., von Spiczak, S., Kroemer, H. K., Runge, U., Boor, R., Stephani, U. and Cascorbi, I.: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics, 19: 353-362 (2009).
31. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. and Willingham, M. C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738 (1987).
32. Fujino, H., Saito, T., Ogawa, S. and Kojima, J.: Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMGCoA reductase. J. Pharm. Pharmacol., 57: 1305-1311 (2005).
33. Huang, Y., Penchala, S., Pham, A. and Wang, J.: Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin. Drug Metab. Toxicol., 4: 237-254 (2008).
34. Li, Y., Wang, Y. and Yang, L.: MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao, 33: 93-104 (2006).
35. Song, P., Lamba, J. K., Zhang, L., Schuetz, E., Shukla, N., Meibohm, B. and Yates, C. R.: G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J. Clin. Pharmacol., 46: 373-379 (2006).
36. Tanaka, T., Uchiumi, T., Hinoshita, E., Inokuchi, A., Toh, S., Wada, M., Takano, H., Kohno, K. and Kuwano, M.: The human multidrug resistance protein 2 gene: Functional characterization of the 5A-flanking region and expression in hepatic cells. Hepatology, 30: 1507-1512 (1999).
37. Laechelt, S., Turrini, E., Ruehmkorf, A., Siegmund, W., Cascorbi, I. and Haenisch, S.: Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J., 11: 25-34 (2011).
38. Hilger, E., Reinthaler, E. M., Stogmann, E., Hotzy, C., Pataraia, E., Baumgartner, C., Zimprich, A. and Zimprich, F.: Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics, 13: 185-190 (2012).
39. Ufer, M., von-Stlpnagel, C., Muhle, H., Haenisch, S., Remmler, C., Majed, A., Plischke, H., Stephani, U., Kluger, G. and Cascorbi, I.: Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics, 21: 624-630 (2011).
40. Becker, M., Elens, L., Visser, L., Hofman, A., Uitterlinden, A., van Schaik, R. and Stricker, B.: Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterollowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J., (2011). [Epub ahead of print]
41. Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y. and Miki, T.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipidlowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet., 19: 375-380 (2004).
42. Donnelly, L. A., Doney, A. S., Tavendale, R., Lang, C. C., Pearson, E. R., Colhoun, H. M., McCarthy, M. I., Hattersley, A. T., Morris, A. D. and Palmer, C. N.: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther., 89: 210-216 (2011).
43. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R.: SLCO1B1 variants and statininduced myopathy-a genomewide study. N. Engl. J. Med., 359: 789-799 (2008).
44. Zhang, W., Chen, B., Ozdemir, V., He, Y., Zhou, G., Peng, D., Deng, S., Xie, Q., Xie, W., Xu, L., Wang, L., Fan, L., Wang, A. and Zhou, H.: SLCO1B1 521T1/4C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol., 64: 346-352 (2007).
45. Yang, G., Yuan, H., Tang, B., Zhang, W., Wang, L., Huang, Z., Ou Yang, D., Zhang, G. and Zhou, H.: Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol. Sin., 31: 382-386 (2010).